View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsPhenomeX 将来の成長Future 基準チェック /26PhenomeX利益と収益がそれぞれ年間38.2%と23.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-21.6% 53.7%なると予測されています。主要情報38.2%収益成長率53.74%EPS成長率Life Sciences 収益成長16.0%収益成長率23.4%将来の株主資本利益率-21.55%アナリストカバレッジGood最終更新日05 Sep 2023今後の成長に関する最新情報Consensus EPS estimates upgraded to US$1.13 loss Aug 24Consensus EPS estimates fall by 22% Aug 21Price target decreased by 29% to US$4.00 Aug 20Price target decreased by 31% to US$5.67 May 19Consensus revenue estimates decrease by 16%, EPS upgraded May 18PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023May 12すべての更新を表示Recent updatesBruker Cellular Analysis, Inc. Files Form 15Oct 13Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic PlatformSep 28PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development WorkflowsSep 22Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free ProteomicsSep 17Consensus EPS estimates upgraded to US$1.13 loss Aug 24Consensus EPS estimates fall by 22% Aug 21Price target decreased by 29% to US$4.00 Aug 20Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).Aug 19New major risk - Share price stability Aug 18New major risk - Financial position Aug 16Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 16PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 11PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement CaseAug 08PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value IndexJun 25+ 2 more updatesPhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price RuleJun 24PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling WorkflowsJun 06Price target decreased by 31% to US$5.67 May 19Consensus revenue estimates decrease by 16%, EPS upgraded May 18PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery WorkflowsMay 16Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)May 16First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 13PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023May 12PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An OpportunityApr 17Full year 2022 earnings: EPS and revenues miss analyst expectations Feb 26Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023Feb 14Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022Jan 10+ 1 more updateBerkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.Dec 23CEO & Director notifies of intention to sell stock Dec 16President of Global Operations notifies of intention to sell stock Nov 25Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell WorkflowNov 19High number of new directors Nov 16Third quarter 2022 earnings: EPS misses analyst expectations Nov 09Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022Nov 09Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022Oct 19Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate SecretarySep 20CEO & Director notifies of intention to sell stock Sep 16President of Global Operations notifies of intention to sell stock Aug 26Consensus revenue estimates fall by 17% Aug 16Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue ForecastsAug 15Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022Aug 10Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer NeoantigenAug 05Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate DevelopmentAug 02Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial OfficerJul 26Mehul Joshi joins Berkeley Lights as CFO Jul 25Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022Jul 22Insider notifies of intention to sell stock May 15First quarter 2022 earnings: EPS misses analyst expectations May 10Price target decreased to US$16.80 Apr 27High number of new directors Apr 27Berkeley Lights, Inc., Annual General Meeting, May 26, 2022Apr 16Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources OfficerApr 14Insider recently bought US$502k worth of stock Mar 12Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning PlatformsMar 05Full year 2021 earnings: EPS and revenues exceed analyst expectations Feb 25Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022Feb 25Price target decreased to US$30.40 Feb 24Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022Feb 11Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead CaseFeb 06ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, IncJan 13High number of new directors Jan 08Berkeley Lights, Inc. Provides Revenue Guidance for Full Year of 2021 and 2022Jan 06Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics ConferenceDec 10Berkeley Lights Grows Revenue But Operating Losses Mount Dec 09Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, IncDec 09Independent Chairman of the Board recently bought US$500k worth of stock Nov 12Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?Nov 07Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.16 loss in 3Q 2020) Nov 05Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions Sep 23Chief Technology Officer notifies of intention to sell stock Sep 18Chief Technology Officer exercised options and sold US$132k worth of stock Sep 04Executive Officer Matthew Rosinack has left the company Sep 03Executive Officer notifies of intention to sell stock Aug 17Price target decreased to US$73.00 Aug 13Second quarter 2021 earnings released: US$0.27 loss per share (vs US$4.25 loss in 2Q 2020) Aug 13Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2021Aug 12Chief Technology Officer exercised options and sold US$357k worth of stock Aug 08CEO & Director exercised options and sold US$697k worth of stock Jul 24Chief Technology Officer exercised options and sold US$362k worth of stock Jul 10Berkeley Lights, Inc.(NasdaqGS:BLI) dropped from Russell 2500 Value IndexJun 28+ 3 more updatesChief Technology Officer notifies of intention to sell stock Jun 11Independent Chairman of the Board recently bought US$206k worth of stock Jun 10Berkeley Lights Releases Subscription-Based Access Program and Signs First CustomersJun 02CEO & Director exercised options and sold US$620k worth of stock May 27Independent Chairman Michael Marks has left the company May 15First quarter 2021 earnings released: US$0.24 loss per share (vs US$3.03 loss in 1Q 2020) May 13Berkeley Lights, Inc. Provides Revenue Guidance for 2021May 12Chief Technology Officer exercised options and sold US$414k worth of stock May 01業績と収益の成長予測NasdaqGS:CELL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025133-47-42-34512/31/2024102-64-51-45612/31/202376-106-60-5466/30/202372-125-68-66N/A3/31/202377-100-61-57N/A12/31/202279-98-56-48N/A9/30/202284-86-65-52N/A6/30/202287-85-68-50N/A3/31/202287-78-72-52N/A12/31/202185-72-69-53N/A9/30/202184-66-54-42N/A6/30/202178-54-45-39N/A3/31/202169-50-40-37N/A12/31/202064-43-39-36N/A9/30/202059-35-33-30N/A6/30/202057-32-31-26N/A3/31/202058-26-27-19N/A12/31/201957-21-19-11N/A12/31/201831-27-21-14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CELL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CELL今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: CELL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CELLの収益 ( 23.4% ) US市場 ( 11.3% ) よりも速いペースで成長すると予測されています。高い収益成長: CELLの収益 ( 23.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CELL 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/04 11:23終値2023/09/29 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PhenomeX Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Gaurav GoparajuBerenbergMark MassaroBTIGTycho PetersonJ.P. Morgan5 その他のアナリストを表示
PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development WorkflowsSep 22
Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free ProteomicsSep 17
Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).Aug 19
PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling WorkflowsJun 06
Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022Jan 10+ 1 more update
Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.Dec 23
Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate SecretarySep 20
Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue ForecastsAug 15
Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer NeoantigenAug 05
Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate DevelopmentAug 02
Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning PlatformsMar 05
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead CaseFeb 06
ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, IncJan 13
Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics ConferenceDec 10
